{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:47:05Z","timestamp":1791665225382,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.euroneuro.2016.10.008","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T05:15:24Z","timestamp":1478927724000},"page":"1941-1949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy"],"prefix":"10.1016","volume":"26","author":[{"given":"Karl","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Torup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Gual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Swift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2016.10.008_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000371547","article-title":"Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients","volume":"21","author":"Aubin","year":"2015","journal-title":"Eur. Addict. Res"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib3","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","article-title":"Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?","volume":"30","author":"Bart","year":"2005","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1369-1600.2011.00366.x","article-title":"The endogenous opioid system in human alcoholics: molecular adaptations in brain areas involved in cognitive control of addiction","volume":"18","author":"Bazov","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/npp.2012.229","article-title":"Affective Cue-Induced Escalation of Alcohol Self-Administration and Increased 22-kHz Ultrasonic Vocalizations during Alcohol Withdrawal: role of Kappa-Opioid Receptors","volume":"38","author":"Berger","year":"2013","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1126\/science.6120570","article-title":"Dynorphin is a specific endogenous ligand of the kappa opioid receptor","volume":"215","author":"Chavkin","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib9","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00228-015-1884-1","article-title":"Severe opioid withdrawal syndrome after a single dose of nalmefene","volume":"71","author":"Donnerstag","year":"2015","journal-title":"Eur. J Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib10","unstructured":"European Medicines Agency, 2016. Committee for medicinal products of human use \/CHMP). Minutes for the meeting on 20\u201323 June 2016. CHMP\/498012\/2016. Available at: \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Minutes\/2016\/07\/WC500211429.pdf\u3009 (23 September, date last accessed)"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib12","unstructured":"European Medicines Agency, 2013. Find medicine - Selincro. Available at: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002583\/WC500140255.pdf> (08 November, date last accessed)"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib70","unstructured":"European Medicines Agency 2010. : Guideline on the development of medicinal products for the treatment of alcohol dependence. EMA\/CHMP\/EWP\/20097\/2008. February 18, 2010. Available at: \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/03\/WC500074898.pdf\u3009"},{"issue":"8","key":"10.1016\/j.euroneuro.2016.10.008_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/add.13438","article-title":"Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers","volume":"111","author":"Fitzgerald","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib14","doi-asserted-by":"crossref","first-page":"e0129289","DOI":"10.1371\/journal.pone.0129289","article-title":"The effects of as-needed nalmefene on patient-reported outcomes and quality of life in relation to a reduction in alcohol consumption in alcohol-dependent patients","volume":"10","author":"Francois","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib15","unstructured":"Food and Drug Administration (FDA), 2015. , Center for Drug Evaluation and Research (CDER): Alcoholism: Developing Drugs for Treatment Guidance for Industry. Available at: \u3008http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm433618.pdf\u3009"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib16","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/alcalc\/agp096","article-title":"Initial preference for drinking goal in the treatment of alcohol problems: i. Baseline differences between abstinence and non-abstinence groups","volume":"45","author":"Heather","year":"2010","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib18","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.pharmthera.2006.02.001","article-title":"Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms","volume":"111","author":"Heilig","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib19","first-page":"433","article-title":"Use of naltrexone in the treatment of alcohol dependence \u2014 a double-blind placebo-controlled Finnish trial","volume":"34","author":"Hein\u00e4l\u00e4","year":"1999","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/10543406.2013.856747","article-title":"An overview of statistical and regulatory issues in the planning, analysis, and interpretation of subgroup analyses in confirmatory clinical trials","volume":"24","author":"Hemmings","year":"2014","journal-title":"J Biopharm. Stat."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib21","unstructured":"Higgins, J.P.T., Green, S. (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from \u3008www.cochrane-handbook.org\u3009"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0306-4603(96)00013-5","article-title":"Drinking goal selection in behavioral self-management treatment of chronic alcoholics","volume":"22","author":"Hodgins","year":"1997","journal-title":"Addict. Behav."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1530-0277.2001.tb02123.x","article-title":"Suppression of ethanol responding by centrally administered CTOP and naltrindole in AA and Wistar rats","volume":"25","author":"Hyytia","year":"2001","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib24","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/sj.npp.1300790","article-title":"Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing","volume":"30","author":"Ingman","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib25","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib26","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.euroneuro.2016.10.008_bib27","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings. A systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/sj.npp.1300338","article-title":"Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol-preferring (P) rats","volume":"29","author":"June","year":"2004","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib29","first-page":"2174","article-title":"The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats","volume":"22","author":"June","year":"1998","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib31","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/npp.2015.183","article-title":"Dissociating motivational from physiological withdrawal in alcohol dependence: role of central amygdala kappa-opioid receptors","volume":"41","author":"Kissler","year":"2016","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.biopsych.2013.03.014","article-title":"The one-two punch of alcoholism: role of central amygdala dynorphins\/kappa-opioid receptors","volume":"75","author":"Kissler","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib33","first-page":"858","article-title":"The treatment gap in mental health care","volume":"82","author":"Kohn","year":"2004","journal-title":"Bull. World Health Organ"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2016.10.008_bib34","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.neuropharm.2008.07.043","article-title":"Neurobiological substrates for the dark side of compulsivity in addiction","volume":"56","author":"Koob","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1192\/bjp.bp.111.096594","article-title":"Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses","volume":"200","author":"Leucht","year":"2012","journal-title":"Br. J Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.15288\/jsad.2007.68.419","article-title":"Moderate drinking in the first year after treatment as a predictor of 3 year outcomes","volume":"68","author":"Maisto","year":"2007","journal-title":"J Stud. Alcohol Drugs"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/adb.12012","article-title":"Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study","volume":"18","author":"Mann","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib38","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0893-133X(97)00113-9","article-title":"Neurobiological similarities in depression and drug dependence: a self-medication hypothesis","volume":"18","author":"Markou","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib40","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0306-4603(02)00294-0","article-title":"Harmreduction approaches to alcohol use: health promotion, prevention, and treatment","volume":"27","author":"Marlatt","year":"2002","journal-title":"Addict. Behav."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib41","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","article-title":"A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence","volume":"18","author":"Mason","year":"1994","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib42","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib43","first-page":"175","article-title":"Binding of a new opiate antagonist, nalmefene, to rat brain membranes","volume":"7","author":"Michel","year":"1985","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.02.012","article-title":"kappa-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats","volume":"61","author":"Nealey","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib45","article-title":"Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials","volume":"22","author":"Palpacuer","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib46","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/0269881115602487","article-title":"Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk","volume":"29","author":"Roerecke","year":"2015","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1037\/0022-006X.52.3.390","article-title":"Random assignment to abstinence and controlled drinking: evaluation of a cognitive-behavioral program for problem drinkers","volume":"52","author":"Sanchez-Craig","year":"1984","journal-title":"J Consult Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib49","series-title":"Summary of Product Characteristics","author":"Selincro\u00ae 18mg film-coated tablets (nalmefene)","year":"2013"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib50","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/alcalc\/36.1.2","article-title":"Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism","volume":"36","author":"Sinclair","year":"2001","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib51","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1360-0443.1995.tb01077.x","article-title":"Controlled drinking after 25 years: how important was the great debate?","volume":"90","author":"Sobell","year":"1995","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib52","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/j.1360-0443.2011.03509.x","article-title":"It is time for low-risk drinking goals to come out of the closet","volume":"106","author":"Sobell","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib53","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0005-7967(73)90118-6","article-title":"Alcoholics treated by individualized behaviour therapy: one year treatment outcome","volume":"11","author":"Sobell","year":"1973","journal-title":"Behav. Res Ther."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0741-8329(97)00131-6","article-title":"A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat","volume":"15","author":"Stromberg","year":"1998","journal-title":"Alcohol"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib55","unstructured":"Substance Abuse and Mental Health Services Administration, 2013: Results from the, 2012. National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-46, HHS Publication No. (SMA) 13\u20134795. Rockville, MD."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0740-5472(02)00319-7","article-title":"Research to practice: adoption of naltrexone in alcoholism treatment","volume":"24","author":"Thomas","year":"2003","journal-title":"J Subst. Abus. Treat."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib57","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0269881113495320","article-title":"Reduced-risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence","volume":"27","author":"van Amsterdam","year":"2013","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib58","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"van den Brink","year":"2013","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib59","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0269881114527362","article-title":"Long-term efficacy, tolerability, and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomised controlled study","volume":"28","author":"van den Brink","year":"2014","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib60","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/14740338.2015.1011619","article-title":"Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme","volume":"14","author":"van den Brink","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib61","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.npp.1301438","article-title":"Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence","volume":"33","author":"Walker","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alcohol.2011.10.006","article-title":"Targeting dynorphin\/kappa opioid receptor systems to treat alcohol abuse and dependence","volume":"46","author":"Walker","year":"2012","journal-title":"Alcohol"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib63","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1369-1600.2010.00226.x","article-title":"Systemic kappa-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats","volume":"16","author":"Walker","year":"2011","journal-title":"Addict. Biol."},{"key":"10.1016\/j.euroneuro.2016.10.008_bib64","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.alcohol.2012.01.001","article-title":"Conceptualizing withdrawal-induced escalation of alcohol self-administration as a learned, plasticity-dependent process","volume":"46","author":"Walker","year":"2012","journal-title":"Alcohol"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib65","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1038\/npp.2013.129","article-title":"Dissociable effects of kappa-opioid receptor activation on impulsive phenotypes in wistar rats","volume":"38","author":"Walker","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib68","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1111\/acer.12543","article-title":"Alcohol methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials","volume":"38","author":"Witkiewitz","year":"2014","journal-title":"Alcohol Clin. Exp. Res"},{"key":"10.1016\/j.euroneuro.2016.10.008_bib69","series-title":"International Guide for Monitoring Alcohol Consumption and Related Harm","author":"World Health Organization (WHO)","year":"2000"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16319708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16319708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T19:50:48Z","timestamp":1536263448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X16319708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0924977X16319708"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.10.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}